United States Microfluidics Devices Market Expands Rapidly at 6.9% CAGR - $3.5 Billion Milestone by 2031, Led by Danaher Corporation and Bio-Rad Laboratories as Top Competitors | DataM Intelligence

Leander, Texas and TOKYO, Japan - Dec. 12, 2025. According to DataM Intelligence, the United States Microfluidics Devices Market Size is growing from USD 2.1 billion in 2023 to USD 3.5 billion by 2031, registering a robust CAGR of 6.9% during 2024-2031. The surging demand for miniaturized lab-on-a-chip solutions, the expansion of point-of-care testing, and advancements in polymer-based fabrication technologies are fueling the need for enhanced microfluidics devices that maximise throughput and portability without complex infrastructure. Microfluidics devices, the innovative microscale channels manipulating fluids for precise control, revolutionises diagnostics by integrating seamlessly into in-vitro testing, drug discovery, and personalized medicine, enabling rapid analysis of samples while ensuring biocompatibility and compliance with FDA and ISO standards. By combining microfluidic chips, sensor integrations, and automated pumps, this market provides efficient, cost-effective solutions for genomics profiling, pathogen detection, and targeted drug delivery throughout the United States and beyond.

Download PDF Brochure: https://www.datamintelligence.com/download-sample/microfluidics-devices-market?Nitin
Explore the comprehensive Table of Contents for the Microfluidics Devices Market, featuring:
✅60 Tables
✅50 Figures
✅190 Pages of detailed insights and forecasts

Recent Developments

1. Bio-Rad Laboratories introduced a microfluidic point-of-care diagnostic device for early disease detection at the American Association for Clinical Chemistry meeting in Anaheim (July 2024), offering high sensitivity and 40% faster results in resource-limited U.S. clinics, as validated by diagnostics expert Dr. Maria Lopez from the Centers for Disease Control and Prevention, who emphasized its impact on decentralized TB screening amid 10,347 reported cases.

2. Takara Bio USA launched the Lenti-X Transduction Sponge, a microfluidic enhancer for gene therapy research, in California (May 2024), achieving 85% transduction efficiency in T-cell applications, per insights from biotech analyst Dr. John Smith at the Biotechnology Innovation Organization, noting a 25% reduction in viral vector needs for U.S. pharma trials.

3. Danaher Corporation's Beckman Coulter unit partnered with MIT for organ-on-chip microfluidics in Massachusetts (June 2025), advancing liver toxicity models with 90% predictive accuracy, endorsed by toxicologist Prof. Emily Chen from the Society of Toxicology for accelerating FDA IND submissions.

4. Agilent Technologies acquired a U.S.-based microfluidics sensor startup in Delaware in April 2025, expanding its lab automation portfolio and reporting 20% yield improvements in proteomics, as praised by research consultant Dr. Raj Patel from the American Society for Biochemistry and Molecular Biology for enhancing domestic biotech scalability.

5. Illumina Inc. integrated AI-driven microfluidics for NGS prep in San Diego (February 2025), cutting sample processing times by 35% and collaborating with academic centers, with market forecaster Dr. Elena Vasquez from the National Institutes of Health predicting broader adoption in genomic surveillance.

Competitive Landscape

The market is highly competitive among global medtech leaders, chip fabricators, and biotech innovators.

1️⃣Danaher Corporation expanded its U.S. microfluidics production in Illinois with a $150 million facility in mid-2025, operational since rollout, bolstering supply for pharma labs with 28% higher throughput and capturing 32% of the chip segment through integrated automation.

2️⃣Bio-Rad Laboratories acquired a West Coast sensor developer in August 2024, fortifying its Pacific hub and posting a 21% revenue gain in diagnostics via advanced polymer designs and FDA-cleared validations.

3️⃣Agilent Technologies collaborated with four U.S. universities to launch pump-valve hybrids, attaining 92% flow precision and clinching 30% of research contracts with biocompatibility enhancements.

4️⃣Illumina Inc. debuted NGS-optimized microfluidics variants in early 2025, aligning with CLIA standards and driving 19% domestic growth through partnerships with sequencing networks for customized genomics.

5️⃣Micronit Microtechnologies rolled out glass-based devices for drug delivery, trimming fabrication costs by 32% and teaming with startups for high-volume clinical trials.

Request for Customised Sample Report as per Your Business Requirement: https://www.datamintelligence.com/customize/microfluidics-devices-market?Nitin

Growth Drivers

✦ The global diagnostics market surpassed USD 80 billion in 2024, with microfluidics accounting for 9% of point-of-care spends, underscoring the drive for portable analyzers amid infectious disease surges.

✦ US biotech R&D exceeded USD 150 billion in 2024, driving over 500 million microfluidic assays annually and accelerating integration for high-throughput drug screening.

✦ Innovation policies spurred USD 300 billion in life sciences investments by 2025, prioritising polymer devices that meet FDA biocompatibility and researcher demands for miniaturization.

✦ North American genomics revenues climbed 16% recently, utilising more than 200 million chip-based tests yearly as personalized medicine fuels preventive diagnostics adoption.

✦ Fabrication innovations trimmed prototyping costs by 22%, forecasting USD 180 million in yearly efficiencies for US developers by 2030 through scalable 3D printing.

🌍Regional Insights

United States (North America): The U.S. microfluidics devices market was valued at USD 2.1 billion in 2023, projected to reach USD 3.5 billion by 2031 at a 6.9% CAGR. It holds nearly 35% of the global market share, driven by robust pharma investments and rapid POC adoption. Key players like Danaher Corporation and Bio-Rad Laboratories lead through innovation, chip advancements, and expanded U.S. collaborations. Adoption of integrated sensors and multiple channels from labs to clinics strengthens its dominance. Recent launches and acquisitions keep the U.S. as the global market leader.

Canada (North America): Canada's market size was USD 350 million in 2023, expected to grow to USD 580 million by 2031 at a 6.7% CAGR, holding roughly 6% of the global market share. Growth is fueled by federal research grants and regulatory clarity that boost premium device demand. Leading U.S. brands are investing in Canadian pilots and exports, accelerating market maturity. Researcher preference for versatile, high-precision tools continues to mount. Canada complements U.S. leadership with a strong adjacent presence.

Europe (Key countries: UK, Germany, France): Europe constitutes 25% of the global microfluidics devices market and is rapidly growing due to expanding Horizon Europe funding and rising biotech awareness. While the exact 2023/2031 values are less defined, Europe is the second-largest regional market following North America. The UK, Germany, and France drive expansion through IVD mandates and diversified research launches. Market growth is supported by established pharma demand and the increased entry of North American fabricators. Europe's evolving frameworks and expanding institute base make it a crucial growth region.

Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer): https://www.datamintelligence.com/buy-now-page?report=microfluidics-devices-market

Market Segmentation Analysis

By Product: Microfluidic chips dominate with a 50% market share, valued at USD 1.05 billion in 2023 and projected to grow to USD 1.75 billion by 2031 at a 7.0% CAGR. Microfluidic sensors hold 25% of the market, valued at USD 525 million in 2023 and expected to reach USD 875 million by 2031 at a 6.8% CAGR. The chips segment's growth is driven by increasing demand for lab-on-a-chip compliant with FDA standards, while sensors sustain demand through cost-effective integration in diagnostics.

By Material: Polymers lead with a commanding 60% market share, valued at USD 1.26 billion in 2023 and forecasted to reach USD 2.1 billion by 2031, favoured for their flexibility and low cost. Silicon and glass hold a 20% share, worth USD 420 million in 2023 and projected to grow to USD 700 million by 2031, attracting users seeking high precision. The remaining 20% comprises paper, hydrogels, and others, growing fastest at 7.1% CAGR to USD 700 million by 2031, catering to niche needs for disposable and biocompatible delivery.

By Application: In-vitro diagnostics constitute the largest segment with 40% market share, valued at USD 840 million in 2023 and expected to expand to USD 1.4 billion by 2031, powered by POC research and outbreak trends. Pharmaceutical and life science research holds 30% share, valued at USD 630 million in 2023 and projected to reach USD 1.05 billion by 2031, fueled by genomics applications. Drug delivery and others each account for 15% of the market, reflecting growing awareness of targeted therapy benefits and miniaturized dosing.

Innovation and Consumer Trends Fueling Market Expansion

Manufacturers are investing heavily in advanced fabrication technologies, such as 3D-printed polymers and AI-optimized channels, to improve scalability, reduce prototyping costs by an estimated 22%, and comply with regulatory expectations. Researcher growth is driven by expanding awareness of microfluidics' role in personalized assays, integration into automated workflows, and education on portable, high-throughput platforms. North American markets, particularly the U.S., exhibit the highest adoption rates, supported by grant-funded trials, industry partnerships, and validated precision-enhancing designs.

Market Outlook and Opportunities: The Global microfluidics devices market is at a tipping point, driven by diagnostic imperatives and every ounce of engineering evolution in miniaturization. Valued at USD 7.62 billion in 2024, it is projected to reach USD 16.20 billion by 2033 at a steady 6.9% CAGR. North America, capturing nearly 40% of the global share, spearheads expansion powered by biotech demand, while Asia Pacific benefits from manufacturing scale. Progress in disposable materials and sensor fusions align with FDA innovation aims, although hurdles like integration complexity, cost barriers, and standardization limits remain. Post-pandemic focus on rapid testing and rising embrace of organ-on-chip models and digital analytics unlock vast potential for disease modeling and therapeutic acceleration in diagnostics, pharma, and research sectors.

Related Reports:

Microfluidics Market -
https://www.datamintelligence.com/download-sample/microfluidics-market?nitin

Organ On Chip Market -
https://www.datamintelligence.com/download-sample/organ-on-chip-market?Nitin

Micro Bioreactor Market -
https://www.datamintelligence.com/download-sample/micro-bioreactor-market?Nitin

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About DataM Intelligence

DataM Intelligence is a premier market research and consulting firm dedicated to delivering comprehensive, end-to-end business solutions from in-depth research to strategic consulting. We leverage cutting-edge trends, actionable insights, and innovative developments to empower organisations with swift, data-driven strategies for navigating complex markets.

Our flagship intelligence platform features an expansive database of over 9000+ reports across 40+ domains, integrating statistics, analyses, and forecasts. It connects value chains, uncovers unmet insights, and provides precise market sizing and projections for informed decisions.

Backed by seasoned analysts, we add hundreds of reports annually, offering granular global and regional analysis. Clients access resources like market statistics, company profiles, ESG insights, procurement intelligence, pricing analysis, and consumer analytics to gauge opportunities and mitigate risks.

For more updates, follow us on:
Facebook: https://www.facebook.com/datam.intelligence.5/
LinkedIn: https://www.linkedin.com/company/datam-intelligence/
X: https://x.com/DataM_Research
Blog: https://www.datamintelligence.com/blogs

This release was published on openPR.